— Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco — ROCKVILLE, Md., Jan. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive topline data from its Phase 2b […]
— First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms — ROCKVILLE, Md., July 12, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome announced today that the European Patent
— New Allowances Bolster Strong SYN-004 Patent Estate — ROCKVILLE, Md., March 1, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the U.S. Patent and Trademark Office (USPTO) issued Notices of Allowance for three patent applications which cover composition
— SYN-010 Demonstrated Ability to Reduce Methane Production, Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores in IBS-C Patients — — Conference Call Wednesday, Jan. 20, 2016, at 8:30 a.m. (ET); Mark Pimentel, MD, FRCP(C) Featured Guest Speaker — ROCKVILLE, Md., Jan. 19, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT:
— SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — First Patients Dosed in Phase 2b Proof-of-Concept Clinical Trial for SYN-004 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE
ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Achieved Planned Milestones for Company’s Lead Microbiome Drug Candidates Enhanced Senior Management Team to Maximize Strategic Opportunities Strengthens Balance Sheet to Support Microbiome Clinical Trials Conference Call Today, August 10, 2015, at 8:30 a.m. EDT Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to
— Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 — — Conference Call Today, August 14, 2014, at 8:30 a.m. (EDT); U.S. Participants Call (877) 870-4263 or Join Webcast at http://www.videonewswire.com/event.asp?id=100224 — ROCKVILLE, Md., Aug. 14,
